Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

John R Lydeard

1PUBLICATIONS

10CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (1)

Sort by Publication Date:

|Feb 04, 2026

A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT.

Muhammad Umair Mushtaq, John F DiPersio, Jacques Azzi

Pageof 1

Frequent Collaborators

1 joint publications

Joseph E Maakaron

1 joint publications

Joseph C Rimando

1 joint publications

Nirali N Shah

1 joint publications

Yonina Keschner

1 joint publications

Giacomo Canesin

1 joint publications

Melissa M Lee-Sundlov

1 joint publications

Julian Scherer

1 joint publications

Michelle I Lin

1 joint publications

Jennifer S Whangbo

1 joint publications

Lori S Muffly

Frequent Collaborators

1 joint publications

Joseph E Maakaron

1 joint publications

Joseph C Rimando

1 joint publications

Nirali N Shah

1 joint publications

Yonina Keschner

Top Related Videos

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on : Oct 17, 2025

See more related videos

Top Related Videos

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on : Oct 17, 2025

See more related videos